The step was one of a series announced by Chinese drug regulators to improve access to treatments and streamline an approval process that foreign suppliers complain is too slow and complex.
The communist government is in the midst of a marathon effort to expand access to health care for China's 1.4 billion people. At the same time, it faces pressure from trading partners to open its markets for medical technology.
"Regarding drugs and medical devices that already are approved to go on the market abroad, they will be allowed on the market with conditions attached," the agency said.
The agency gave no details of what products might be affected or how the approval process would work.
Suppliers of drugs and devices such as X-ray machines have long looked at China as a promising market but complain that a cumbersome approval process that can take up to seven years hampers market access.
In 2015, the CFDA promised to simplify drug approvals and clear a backlog of applications.
Also today, the CFDA said it would streamline the process for approving generic drugs, a step that could undercut potential demand for foreign products.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
